Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Zirabev [legacy through FY23] by Year
Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)
Pfizer Zirabev [legacy through FY23]: $27M in FY2023, down 28.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Zirabev | 75 | 100 | (25%) | (26%) | 27 | 38 | (30%) | (25%) | 18 | 11 | 64% | 89%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 27 | -28.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 38 | 0.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 38 | +111.1% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 18 | +1,700.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 1 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
Breakdown
What makes up zirabev [legacy through FY23]
Cite this data
StockData. (2026). Pfizer Zirabev [legacy through FY23] ($M), annual FY2019–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.